Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam

Kosmas Tsakiridis, Andreas Mpakas, George Kesisis, Stamatis Arikas, Michael Argyriou, Stavros Siminelakis, Paul Zarogoulidis, Nikolaos Katsikogiannis, Ioanna Kougioumtzi, Theodora Tsiouda, Eirini Sarika, Ioanna Katamoutou, Konstantinos Zarogoulidis

Abstract

The majority of patients survive after extracorporeal circulation without any clinically apparent deleterious effects. However, disturbances exist in various degrees sometimes, which indicate the harmful effects of cardiopulmonary bypass (CPB) in the body. Several factors during extracorporeal circulation either mechanical dependent (exposure of blood to non-biological area) or mechanical independent (surgical wounds, ischemia and reperfusion, alteration in body temperature, release of endotoxins) have been shown to trigger the inflammatory reaction of the body. The complement activation, the release of cytokines, the leukocyte activation and accumulation as well as the production of several “mediators” such as oxygen free radicals, metabolites of arachidonic acid, platelet activating factors (PAF), nitric acid, and endothelin. The investigation continues today on the three metabolites of lornoxicam (the hydroxylated metabolite and two other metabolites of unknown chemical composition) to search for potential new pharmacological properties and activities.